Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
This comprehensive resource covers product change evaluation, postmarket surveillance, audit/inspection compliance, and various other laws and regulations pertaining to maintaining a product on the market.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Regulatory News | 13 October 2017 | By Zachary Brennan
As more cancer drugs are approved and prices continue to rise, questions have circulated on whether these drugs are extending patient survival or improving quality of life (QoL).
A research article published in the BMJ last week reviewed the approval of drugs by the European Medicines Agency (EMA) from 2009 to 2013 and noted that most drugs entered the market without evidence of survival benefits or QoL.
"When there were survival gains over existing treatment options or placebo, they were often marginal," the UK and Latvian professors who conducted the research noted in its conclusion.
The BMJ research is part of a large and growing number of questions circulating on gains made with recent cancer drug approvals.
Vinay Prasad, assistant professor of medicine at Oregon Health and Science University, has been a vocal critic of the wave of recent approvals and wrote the accompanying editorial to the BMJ article, in which he called the regulatory system "broken." He's previously written in Focus on how most cancer drugs "cost too much and give us too little" in response to an op-ed in Focus on a JAMA study he co-authored.
Back in June, Richard Pazdur, FDA's director of the Oncology Center of Excellence, also discussed in a blog post how to measure patient benefit with cancer treatment.
But rather than refute the BMJ article’s findings in a response published Thursday, Francesco Pignatti, head of oncology, hematology and diagnostics at the EMA, wrote that the article’s findings "are not surprising to anyone familiar with cancer drug development."
And Pignatti offered four reasons why in many situations "demonstrating a clear effect on survival or QoL is not feasible and a benefit can be shown on the basis of other endpoints":
Pignatti adds that conducting trials "according to the most rigorous methodology is strongly encouraged" but is not "a pre-requisite for approval provided that existing uncertainties can be addressed on the basis of the totality of the data, including future studies, where appropriate … restricting approvals of cancer drugs only to situations where there is indisputable evidence of improvement in survival or QoL will not improve the lives of cancer patients."
Tags: cancer drug approvals, QoL, survival benefit